Abeona Stock Falls 39% on Monday as Company Reports Q3 Results and Announces Acquisition and Private Placement

Abeona Therapeutics (Nasdaq: ABEO) shares fell 39.1% on Monday, closing at $2.54 against a previous close of $4.17, while the S&P 500 ETF (SPY) rose 2.37% in the same session. Volume reached 15.3 times its normal level. The company did not state a single reason for the decline, but it released its third-quarter results and two transaction announcements before the open on the same day.

Quarterly results and the transactions filed alongside them

In an 8-K filed at 6:35 a.m. ET, Abeona reported net ZEVASKYN revenue of $13.5 million for the quarter ended Sept. 30, 2026, up 18% from $11.4 million in the second quarter. Net loss was $4.8 million, or $0.08 per share, narrower than the $20.2 million loss in the second quarter. Cash, cash equivalents and short-term investments totaled $134.9 million at quarter end, excluding a $30 million private placement completed after the period.

In a separate 8-K filed at 6:30 a.m. ET, Abeona disclosed it had acquired APT-1011, now ABO-801, a Phase 3-ready treatment for eosinophilic esophagitis, from Ellodi Pharmaceuticals. Abeona issued Ellodi $20 million of common stock, 4,494,383 shares, with no upfront cash payment. Ellodi is also eligible for $30 million upon FDA approval and up to $30 million on sales milestones.

Dilution from the private placement

The same filing describes a private placement of 6,400,000 shares of common stock and pre-funded warrants for 1,600,043 shares, for about $30 million in aggregate. The shares were priced at $3.75 each, below the previous close of $4.17. Morgan Stanley was the placement agent. The closing is expected on Nov. 10, 2026.

Cash position against the loss rate

At Sept. 30, the company reported $134.9 million in cash, cash equivalents and short-term investments. Selling, general and administrative expenses were $17.1 million in the quarter. The filings do not link any specific item to the share decline.